ReviewCerebellum (London, England)2026
Case Report and Literature Review of Mycoplasma Pneumoniae Associated Opsoclonus-Myoclonus-Ataxia Syndrome.
Review in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma pneumoniae (MP) is a common respiratory pathogen, but in addition to respiratory tract infection, it can also involve the nervous system, cardiovascular and so on. Nervous system is the most common extrapulmonary complication of MP infection, with a total incidence of about 0.1%. Opsoclonus-myoclonus-ataxia syndrome (OMAS) associated with MP sensation has been reported, but the number of OMAS has been few, and there are few reports on the clinical characteristics and treatment response of the disease. Since the animal model of extrapulmonary manifestations caused by MP has not been established, the characteristics and treatment of this disease need to be accumulated from clinical patients. Here, we report a 13-year-old boy who presented with opsoclonus, myoclonus, and ataxia after 4 days of cough and fever. In addition, we summarized the characteristics of 9 previously reported MP associated OMAS patients and this patient, compared their clinical features, treatment and prognosis.
Indexed as
Identifiers
41697567What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.